MXPA03003983A - Formulaciones que comprenden polimeros de dextrina en combinacion con azucares para la administracion de acidos nucleicos. - Google Patents

Formulaciones que comprenden polimeros de dextrina en combinacion con azucares para la administracion de acidos nucleicos.

Info

Publication number
MXPA03003983A
MXPA03003983A MXPA03003983A MXPA03003983A MXPA03003983A MX PA03003983 A MXPA03003983 A MX PA03003983A MX PA03003983 A MXPA03003983 A MX PA03003983A MX PA03003983 A MXPA03003983 A MX PA03003983A MX PA03003983 A MXPA03003983 A MX PA03003983A
Authority
MX
Mexico
Prior art keywords
formulations
nucleic acids
combination
delivery
sugars
Prior art date
Application number
MXPA03003983A
Other languages
English (en)
Inventor
Heidrun Engler
Original Assignee
Ml Lab Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026892A external-priority patent/GB0026892D0/en
Priority claimed from GB0110525A external-priority patent/GB0110525D0/en
Priority claimed from GB0112585A external-priority patent/GB0112585D0/en
Application filed by Ml Lab Plc filed Critical Ml Lab Plc
Publication of MXPA03003983A publication Critical patent/MXPA03003983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
MXPA03003983A 2000-11-03 2001-11-02 Formulaciones que comprenden polimeros de dextrina en combinacion con azucares para la administracion de acidos nucleicos. MXPA03003983A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0026892A GB0026892D0 (en) 2000-11-03 2000-11-03 Nucleic acid delivery
GB0110525A GB0110525D0 (en) 2001-04-30 2001-04-30 Nucleic acid delivery
GB0112585A GB0112585D0 (en) 2001-05-24 2001-05-24 Nucleic acid delivery
PCT/GB2001/004878 WO2002036167A1 (en) 2000-11-03 2001-11-02 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids

Publications (1)

Publication Number Publication Date
MXPA03003983A true MXPA03003983A (es) 2003-08-19

Family

ID=27255959

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003983A MXPA03003983A (es) 2000-11-03 2001-11-02 Formulaciones que comprenden polimeros de dextrina en combinacion con azucares para la administracion de acidos nucleicos.

Country Status (10)

Country Link
EP (1) EP1330265B1 (es)
JP (1) JP4426757B2 (es)
AT (1) ATE431748T1 (es)
AU (2) AU2002212486B2 (es)
CA (1) CA2426334C (es)
DE (1) DE60138762D1 (es)
ES (1) ES2327491T3 (es)
MX (1) MXPA03003983A (es)
NZ (1) NZ525362A (es)
WO (1) WO2002036167A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
JP2008521575A (ja) * 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法
US20180021367A1 (en) * 2015-01-30 2018-01-25 Fresenius Kabi Deutschland Gmbh Use of a mixture of modified glucose polymers for reducing tumor metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233715B1 (en) * 1986-01-31 1994-05-25 BEECHAM GROUP plc Isolation and expression of genes involved in the biosynthesis of beta-lactams
DE19748290B8 (de) * 1997-10-31 2009-09-03 Fresenius Medical Care Deutschland Gmbh Lösung für die Peritonealdialyse
IL147500A0 (en) * 1999-08-10 2002-08-14 Ml Lab Plc Method for delivery of therapeutic agents using a solution of dextrin

Also Published As

Publication number Publication date
CA2426334C (en) 2011-09-20
EP1330265A1 (en) 2003-07-30
ES2327491T3 (es) 2009-10-30
ATE431748T1 (de) 2009-06-15
JP4426757B2 (ja) 2010-03-03
AU1248602A (en) 2002-05-15
NZ525362A (en) 2004-11-26
CA2426334A1 (en) 2002-05-10
AU2002212486B2 (en) 2007-10-04
WO2002036167A8 (en) 2002-09-26
JP2004512380A (ja) 2004-04-22
EP1330265B1 (en) 2009-05-20
WO2002036167A1 (en) 2002-05-10
DE60138762D1 (de) 2009-07-02

Similar Documents

Publication Publication Date Title
GB2365867B (en) Vector constructs
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
AU2001290706A1 (en) Antisense modulation of clusterin expression
BR9910251A (pt) Estimulação hematopoiética
EP1483281A4 (en) METHOD FOR THE PRODUCTION OF INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC APPLICATIONS OF SUCH MOLECULES
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
AU7621600A (en) Human rnase h and oligonucleotide compositions thereof
AU2002214596A1 (en) Methods and compositions for nucleic acid delivery
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
ES2249058T3 (es) Factores de preservacion de celulas progenitoras y metodos y productos relacionados.
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003060066A8 (en) Nucleic acid delivery and expression
AU1248602A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
WO2001000854A3 (en) Chimeric proteins mediating targeted apoptosis
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
ZA200202481B (en) Recombinant adenoviruses preparation and adenovirus banks.
EP1248635A4 (en) ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
WO1999059638A3 (en) Compositions and methods for the delivery of nucleic acid molecules
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung
WO2000034500A3 (en) Methods for increasing the efficiency of gene transfer

Legal Events

Date Code Title Description
HC Change of company name or juridical status
HC Change of company name or juridical status
FG Grant or registration